RPG LIFE SCIENCES LTD

Sells branded pharmaceutical formulations in India and abroad, and through mid-2026 also manufactured active pharmaceutical ingredients (APIs). Domestic Formulations is the largest segment — it markets chronic-therapy drugs under brands such as Naprosyn, launched a new Naprosyn ES (Naproxen + Esomeprazole) combination in July 2026 through a partnership with Archerchem, and is scaling an immunosuppressant portfolio. International Formulations exports formulations to overseas markets. The API business, which contributed Rs 95.06 crore (13.54% of FY26 consolidated revenue), is being transferred on a slump sale basis to a newly formed wholly owned subsidiary, RPG Active Pharma, in which PE investors are committing up to Rs 700 crore; the same subsidiary is separately acquiring 100% of Actis Generics for Rs 80 crore in cash. Raw materials (19.2% of revenue) and employees (20.0% of revenue) are the largest operating costs, with capex at 9.2% and depreciation at 3.0% of revenue. FY26 consolidated revenue totalled Rs 707.52 crore, with Domestic Formulations at Rs 483.5 crore growing 13.8% year-on-year while International Formulations declined 6.7%.